Wedbush Reiterates Outperform on Travere Therapeutics, Maintains $76 Price Target

Benzinga Newsdesk www.benzinga.com Negative 70.2%

Neg 70.2% Neu 0% Pos 0%

Wedbush analyst Laura Chico reiterates Travere Therapeutics (NASDAQ:TVTX) with a Outperform and maintains $76 price target.